Search Result

Results for "

Hsp90 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (4) Akt (1) Androgen Receptor (1) Antibiotic (7) Apoptosis (29) Autophagy (11) Bacterial (7) Beta-lactamase (1) DNA/RNA Synthesis (2) Drug Metabolite (1) EGFR (1) ERK (1) Estrogen Receptor/ERR (4) FAK (1) FKBP (1) Fungal (2) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HSP (106) HSV (1) Influenza Virus (2) JNK (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitophagy (1) Monoamine Oxidase (2) mTOR (1) Necroptosis (1) NF-κB (1) Orthopoxvirus (2) Parasite (2) PDHK (2) PKC (1) Potassium Channel (2) PROTACs (2) Reactive Oxygen Species (1) RIP kinase (1) Topoisomerase (1) VEGFR (2)
By Research Areas:	Cancer (97) Cardiovascular Disease (1) Infection (16) Inflammation/Immunology (10) Metabolic Disease (2) Neurological Disease (7)
Click Chemistry:	Alkynes (1)

116

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149531

HSP90-IN-25

HSP Cancer

HSP90-IN-25 (compound 4a) is an HSP90 inhibitor that specifically inhibits the ATPase activity of HSP90 .

HSP90-IN-25	HSP	Cancer
HSP90-IN-25 (compound 4a) is an HSP90 inhibitor that specifically inhibits the ATPase activity of HSP90 .

HY-152027

HSP90-IN-18	HSP Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
HSP90-IN-18 is an effective *heat shock protein 90 (Hsp90)* inhibitor. HSP90-IN-18 has effective Hsp90 inhibitory activity with an IC₅₀ value of 0.39 μM. HSP90-IN-18 can be used for the research of viral infection, neurodegenerative disease, and inflammation .

HY-152028

HSP90-IN-19	HSP	Infection Neurological Disease Inflammation/Immunology Cancer
HSP90-IN-19 is an effective *heat shock protein 90 (Hsp90)* inhibitor. HSP90-IN-19 has effective Hsp90 inhibitory activity with an IC₅₀ value of 0.27 μM. HSP90-IN-19 can be used for the research of viral infection, neurodegenerative disease, and inflammation .

HY-150655

Hsp90-IN-15	HSP	Cancer
Hsp90-IN-15 is an *Hsp90* inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of *Hsp90* in Hela cell .

HY-144724

HSP90-IN-10	HSP Apoptosis	Cancer
HSP90-IN-10 (Compound 16s) is a potent inhibitor of *HSP90. HSP90-IN-10 exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC₅₀* value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .

HY-151337

Aha1/Hsp90-IN-1	Microtubule/Tubulin	Neurological Disease Inflammation/Immunology
Aha1/Hsp90-IN-1 (Compound 17) is an Aha1/Hsp90 complex inhibitor. Aha1/Hsp90-IN-1 disrupts Aha1/Hsp90 interactions with an IC₅₀ of 3.32 μM. Aha1/Hsp90-IN-1 inhibits tau aggregation .

HY-156779

HSP90-IN-27

HSP Cancer

HSP90-IN-27 (compound 19) is an HSP90 inhibitor .

HSP90-IN-27	HSP	Cancer
HSP90-IN-27 (compound 19) is an *HSP90* inhibitor .

HY-113574

HSP90-IN-29	HSP	Cancer
HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective *HSP-90* inhibitor with an IC₅₀ value of 30 nM. HSP90-IN-29 has antitumor activity .

HY-149780

Flavokawain 1i

DiNap
HSP Cancer

Flavokawain 1i (DiNap) is an Hsp90 inhibitor. Flavokawain 1i (DiNap) has anti-cell proliferation activity and can be used in cancer research .
HY-148963

HSP90-IN-20

HSP Cancer

HSP90-IN-20 (compound 78p) is a potent HSP90 inhibitor with an IC₅₀ of ≤10 μM. HSP90-IN-20 has the potential for cancers research .

Flavokawain 1i DiNap	HSP	Cancer
Flavokawain 1i (DiNap) is an *Hsp90* inhibitor. Flavokawain 1i (DiNap) has anti-cell proliferation activity and can be used in cancer research .

HSP90-IN-20	HSP	Cancer
HSP90-IN-20 (compound 78p) is a potent *HSP90* inhibitor with an IC₅₀ of ≤10 μM. HSP90-IN-20 has the potential for cancers research .

HY-145814

HSP90-IN-9	HSP Fungal	Infection
HSP90-IN-9 is a potent and selective *HSP90* inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .

HY-146325

HSP90-IN-11	HSP	Cancer
HSP90-IN-11 (Compound 12c) is a potent inhibitor of *HSP90. HSP90-IN-11 displays potent HSP90α inhibition comparable to AUY-922 (Luminespib). HSP90-IN-11 shows significant antiproliferative activity in CRC and NSCLC cells in a double digit nM range. HSP90-IN-11 leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. HSP90*-IN-11 induces significant accumulation of a sub-G1 phase population .

HY-151137

HSP90/mTOR-IN-1	mTOR HSP Apoptosis Autophagy	Cancer
HSP90/mTOR-IN-1 is a potent and orally active *Hsp90* and mTOR inhibitor with IC₅₀ values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .

HY-149891

HSP90-IN-23	HSP	Cancer
HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC₅₀ of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .

HY-144650

Hsp90-Cdc37-IN-3	Apoptosis HSP	Cancer
Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits *Hsp90−Cdc37* by covalent-binding, and induces apoptosis .

HY-163288

EZH2/HSP90-IN-29	Histone Methyltransferase HSP Apoptosis	Cancer
EZH2/HSP90-IN-29 is a dual inhibitor for EZH2 and *HSP90, with IC₅₀s of 6.29 nM and 60.1 nM, for EZH2 and HSP90, respectively. EZH2/HSP90-IN-29 increases apoptosis/necrosis-related gene expression, induces cell cycle arrest at M phase and inhibits* reactive oxygen species (ROS) catabolism pathway. EZH2/HSP90-IN-29 is able to cross the blood-brain-barrier (BBB) .

HY-148215

Hsp90-IN-17

HSP Cancer

Hsp90-IN-17 (Example 5) is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

Hsp90-IN-17	HSP	Cancer
Hsp90-IN-17 (Example 5) is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-148215A

Hsp90-IN-17 hydrochloride	HSP	Cancer
Hsp90-IN-17 (Example 5) hydrochloride is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-10210

Retaspimycin Hydrochloride

3 Publications Verification

IPI-504
HSP Cancer

Retaspimycin Hydrochloride is a potent inhibitor of Hsp90 with EC₅₀s of 119 nM for both Hsp90 and Grp9.
HY-10389

Alvespimycin

10+ Cited Publications

17-DMAG; NSC 707545
HSP Cancer

Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC₅₀ of 62 ± 29 nM.
HY-15263

Retaspimycin

HSP Cancer

Retaspimycin is a potent inhibitor of Hsp90, with EC₅₀s of 119 nM for both Hsp90 and Grp9.

Retaspimycin Hydrochloride 3 Publications Verification IPI-504	HSP	Cancer
Retaspimycin Hydrochloride is a potent inhibitor of *Hsp90* with EC₅₀s of 119 nM for both Hsp90 and Grp9.

Alvespimycin 10+ Cited Publications 17-DMAG; NSC 707545	HSP	Cancer
Alvespimycin (17-DMAG) is a potent inhibitor of *Hsp90, binding to Hsp90* with an EC₅₀ of 62 ± 29 nM.

Retaspimycin	HSP	Cancer
Retaspimycin is a potent inhibitor of *Hsp90, with EC₅₀s of 119 nM for both Hsp90* and Grp9.

HY-150774

HDAC6/HSP90-IN-2	HDAC HSP Apoptosis	Cancer
HDAC6/HSP90-IN-2 (compound 6e) is a dual inhibitor of HDAC6 and *Hsp90, with IC₅₀s of 105.7 and 61 nM, respectively. HDAC6/HSP90*-IN-2 can be used for the research of cancer .

HY-111414

Hsp90-Cdc37-IN-1

HSP Cancer

Hsp90-Cdc37-IN-1 is an Hsp90-Cdc37 interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC₅₀ of 140 nM.

Hsp90-Cdc37-IN-1	HSP	Cancer
Hsp90-Cdc37-IN-1 is an *Hsp90-Cdc37* interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC₅₀ of 140 nM.

HY-10214

SNX-2112 2 Publications Verification PF-04928473	HSP Autophagy	Cancer
SNX-2112 (PF 04928473) is an orally active *Hsp90* inhibitor, with a K_d of 16 nM for *Hsp90* and IC₅₀s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC₅₀s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with K_ds of 4 nM, 6 nM and 484 nM, respectively .

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent *HSP90* pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .

HY-151335

KU-177	HSP	Cancer
KU-177 is a potent inhibitor of *Hsp90* ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts *Aha1/Hsp90* interactions (IC₅₀=4.08 μM) without inhibition of Hsp90’s ATPase activity. KU-177 can be used for tauopathies research .

HY-158131

FKBP51-Hsp90-IN-2	FKBP HSP	Neurological Disease Cancer
FKBP51-Hsp90-IN-2 (Compound E08) is a selective *FKBP51-Hsp90* protein-protein interaction inhibitor with IC₅₀ values of 0.4 µM and 5 µM for FKBP51 and FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of *HSP90* in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on *HSP90* protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146293

HDAC6/HSP90-IN-1	HDAC HSP	Cancer
HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of HDAC6 and *HSP90, with IC₅₀* values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice .

HY-12024

Alvespimycin hydrochloride 10+ Cited Publications 17-DMAG hydrochloride; KOS-1022; BMS 826476	HSP Apoptosis	Cancer
Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of *Hsp90, binding to Hsp90* with EC₅₀ of 62±29 nM.

HY-125759

3-Phenyltoxoflavin	HSP	Cancer
3-Phenyltoxoflavin, a derivative of Toxoflavin, is an *Hsp90* inhibitor, with a K_d of 585 nM for the interaction of Hsp90-TPR2A. 3-Phenyltoxoflavin has anti-cancer activity .

HY-130851

HS-27	HSP	Cancer
HS-27, a fluorescently-tethered *Hsp90* inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer .

HY-155577

MAO A/HSP90-IN-1	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC₅₀ value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which inhibits T cell activation. MAO A/HSP90-IN-1 (4-b) have potential to inhibit tumor immune escape. MAO A/HSP90-IN-1 (4-b) can be used for brain tumor-related diseases research .

HY-147974

HSP90-IN-14	HSP Influenza Virus	Infection
HSP90-IN-14 (compound 4) is a potent *Hsp90* (heat shock protein 90) inhibitor, with a K_d of 0.26 μM. HSP90-IN-14 shows anti-influenza virus activity in MDCK cells, with EC₅₀ values of 2.6, 3.9, and 17 μM for influenza A/H3N2, A/H1N1, and B, respectively .

HY-153588

HSP90-IN-22	HSP	Cancer
HSP90-IN-22 (Compound 35) is an Hsp90 inhibitor with antiproliferative properties on cells with IC₅₀ values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells, respectively.

HY-144694

HDAC/HSP90-IN-3	HSP HDAC Fungal	Infection
HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal *Hsp90* and HDAC dual inhibitor, with IC₅₀ values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1 .

HY-133705

Geldanamycin-FITC	HSP	Others
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-10215

Luminespib 15+ Cited Publications VER-52296; AUY922; NVP-AUY922	HSP Autophagy Apoptosis	Cancer
Luminespib (VER-52296) is a potent *HSP90* inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .

HY-13469

Debio 0932 3 Publications Verification CUDC-305	HSP	Cancer
Debio 0932 (CUDC-305) is an orally active *HSP90* inhibitor, with IC₅₀s of 100 and 103 nM for HSP90α and HSP90β, respectively .

HY-15986

VER-49009

CCT 129397
HSP Cancer

VER-49009 is a Hsp90 inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

VER-49009 CCT 129397	HSP	Cancer
VER-49009 is a *Hsp90* inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

HY-119046

SNX-0723	HSP Parasite	Infection
SNX-0723 is a potent *Hsp90* Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC₅₀ of 3.3 μM .

HY-10211

Tanespimycin 30+ Cited Publications 17-AAG; NSC 330507; CP 127374	HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (17-AAG) is a potent *HSP90* inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-15984

VER-50589

1 Publications Verification

HSP Apoptosis Cancer

VER-50589 is a Hsp90 inhibitor, with an IC₅₀ of 21 nM and a K_d of 4.5 nM.

VER-50589 1 Publications Verification	HSP Apoptosis	Cancer
VER-50589 is a *Hsp90* inhibitor, with an IC₅₀ of 21 nM and a K_d of 4.5 nM.

HY-107577

Gedunin	HSP	Infection Inflammation/Immunology Cancer
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-117395

PU-H54	HSP	Cancer
PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15190

NVP-HSP990 2 Publications Verification Hsp-990	HSP Apoptosis	Cancer
NVP-HSP990 is a potent, selective and orally active *Hsp90* inhibitor, with IC₅₀ values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

HY-14463

Onalespib

5+ Cited Publications

AT13387
HSP Cancer

Onalespib (AT13387) is a long-acting second-generation Hsp90 inhibitor with a K_d of 0.71 nM.
HY-13313

XL888

2 Publications Verification

HSP Cancer

XL888 is a heat shock protein-90 (HSP90) inhibitor, with an IC₅₀ of 24 nM.

HY-114413

YZ129	HSP Apoptosis	Cancer
YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to heat shock protein 90 (HSP90) with an IC₅₀ of 820 nM on NFAT nuclear translocation. YZ129-induced GBM cell-cycle arrest at the G2/M phase promotes apoptosis and inhibited tumor cell proliferation and migration .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107577

Gedunin	Infection Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-N0754

Eupalinolide A	Classification of Application Fields Melilotus albus Desr. Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Inflammation/Immunology	HSP
Eupalinolide A, isolated from Eupatorium lindleyanum, induces the expression of HSP70 via the activation of HSF1 by inhibiting the interaction between HSF1 and HSP90 .

HY-15230

Geldanamycin Maximum Cited Publications 21 Publications Verification	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Inflammation/Immunology Disease Research Fields	HSP Bacterial Influenza Virus Antibiotic
Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-119906

Conglobatin FW-04-806	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-N10393

Vibsanin A	Structural Classification Natural Products Classification of Application Fields Viburnaceae Source classification Viburnum awabuki K. Koch Plants Disease Research Fields Cancer	PKC HSP
Vibsanin A, a protein kinase C (PKC) activator, exhibits anti-proliferative activity against human cancer cell lines. Vibsanin A is also a *HSP90* inhibitor .

HY-N3417

Kongensin A	Classification of Application Fields Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields Croton kongensis Gagnep.	HSP RIP kinase Apoptosis Necroptosis
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent *HSP90* inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-108486

Herbimycin A	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Disease Research Fields	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-B0425A

Novobiocin sodium 5 Publications Verification Albamycin sodium; Cathomycin sodium	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Antiviral Antibacterial Disease Research Disease Research Fields Other Antibiotics Cancer	Bacterial Antibiotic Orthopoxvirus Apoptosis DNA/RNA Synthesis HSP
Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity .

HY-N10502

Colletofragarone A2	Other Terpenoids Structural Classification Microorganisms Terpenoids	MDM-2/p53 HSP
Colletofragarone A2 can be be isolated from the fungus Colletotrichum sp. (13S020). Colletofragarone A2 inhibits mutant p53 and *HSP90* with anti-cancer activity. Colletofragarone A2 promotes degradation and aggregation of mutant p53 and suppressing tumor growth in vivo .

HY-N6769

Radicicol 3 Publications Verification Monorden	Structural Classification Antifungal Classification of Application Fields Source classification Marine natural products Anti-parasitic Disease Research Infection Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Disease Research Fields Marine microorganism	HSP Bacterial Antibiotic Parasite
Radicicol is an inhibitor of *Hsp90* with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-B1434

7-Aminocephalosporanic acid 1 Publications Verification 7-ACA	Infection Classification of Application Fields Disease Research Fields	Beta-lactamase Bacterial Antibiotic
7-aminocephalosporanic acid (7-ACA) is a *HSP90β* inhibitor and an antibiotic. 7-Aminocephalosporanic acid is the core chemical structure of the synthesis of cephalosporin antibiotics and an effective β-lactamase inhibitor .

Cat. No.	Product Name	Chemical Structure

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks